RecruitingNCT06978660

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis (CONCERTO)

Sponsor

Idoven 1903 S.L.

Enrollment

2,200 participants

Start Date

May 27, 2025

Study Type

OBSERVATIONAL

Conditions

Transthyretin Cardiac Amyloidosis

Summary

CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with transthyretin cardiac amyloidosis. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(8)

Northwestern University

Evanston, Illinois, United States

Centre Hospitalier Universitaire de Toulouse

Toulouse, France

Universitätsklinikum Bonn

Bonn, Germany

TUM Klinikum Deutsches Herzzentrum

München, Germany

Hospital Universitario Son Llàtzer

Palma de Mallorca, Balearic Islands, Spain

Hospital Universitario Donostia

San Sebastián, Guipúzcoa, Spain

Hospital Universitario Juan Ramón Jiménez

Huelva, Huelva, Spain

Queen Elizabeth University Hospital, Univeisity of Glasgow

Glasgow, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06978660

Related Trials

Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

NCT054895234 locations

Exercise Training in Transthyretin Cardiac Amyloidosis

NCT057978571 location